Sparrow2 schreef op 13 mrt 2019 om 11:52:
Van WallStreet Trader op het Inhoudelijk Light draadje.
This trial is ongoing. It must report results 6 days, 13 hours from now.
Full entry on ClinicalTrials.gov
A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment
Required reporting date March 20, 2019, midnightfdaaa.trialstracker.net/trial/NCT0287...